open access

Vol 94, No 7 (2023)
Research paper
Published online: 2023-03-27
Get Citation

Influence of gestational diabetes mellitus on outcomes of preinduced labour with dinoprostone vaginal insert

Magdalena Kolak1, Katarzyna Skibinska1, Magda Rybak-Krzyszkowska1, Agnieszka Micek2, Tomasz Gora3, Hubert Huras1, Andrzej P. Jaworowski1
·
Pubmed: 36976868
·
Ginekol Pol 2023;94(7):539-543.
Affiliations
  1. Department of Obstetrics & Perinatology, Jagiellonian University Medical College, Cracow, Poland
  2. Department of Nursing Management and Epidemiological Nursing, Jagiellonian University, Collegium Medicum, Cracow, Poland
  3. Department of Gynecology and Obstetrics, City Hospital, Rzeszow, Poland

open access

Vol 94, No 7 (2023)
ORIGINAL PAPERS Obstetrics
Published online: 2023-03-27

Abstract

Objectives: The aim of this study was to evaluate the effectiveness of labour preinduction using a dinoprostone vaginal insert in patients with gestational diabetes mellitus versus patients undergoing labour induction for other causes. The second aim of the study was to compare perinatal outcomes in both groups.

Material and methods: The study has a retrospective character, conducted in 2019–2021 in a tertiary reference hospital. The following endpoints were assumed for the analysis: natural childbirth, birth occurring within 12 hours of dinoprostone administration and neonatal outcomes. Furthermore, indications of a caesarean section were analysed.

Results: The percentage of natural childbirths was similar in both groups. Furthermore, in both groups, over 80% of patients gave birth within less than 12 hours following dinoprostone administration. Neonatal outcomes (body weight, Apgar score) did not differ statistically. Analysing indications for a caesarean section, failure in the progress of labour was an indication in 39.5% of cases in the control group, 29.4% of cases in gestational diabetes mellitus (GDM), and 50% of cases in diabetes mellitus (DM). The risk of foetal asphyxia was an indication in 55.8% of cases in the control group, 35.3% of cases in GDM and 50% of cases in DM. Ineffective labour induction — no induction of the contractile function was an indication for a C-section in 4.7% of cases in the control group and 35.3% of cases in GDM; no cases were noted in DM (p = 0.024).

Conclusions: The study demonstrated that patients undergoing labour induction due to GDM using a dinoprostone vaginal insert did not differ in terms of labour duration, oxytocin administration compared to patients undergoing labour induction for other causes. Furthermore, the same rate of caesarean sections was found in the study group; however, these groups differ in terms of indications, including risk of foetal asphyxia (35.3% vs 55.8%), failure in the progress of labour (29.4% vs 39.5%), and no active labour (1.8% vs 1.5%). The neonatal Apgar score at 1.5 and 10 minutes after birth was similar in both groups.

Abstract

Objectives: The aim of this study was to evaluate the effectiveness of labour preinduction using a dinoprostone vaginal insert in patients with gestational diabetes mellitus versus patients undergoing labour induction for other causes. The second aim of the study was to compare perinatal outcomes in both groups.

Material and methods: The study has a retrospective character, conducted in 2019–2021 in a tertiary reference hospital. The following endpoints were assumed for the analysis: natural childbirth, birth occurring within 12 hours of dinoprostone administration and neonatal outcomes. Furthermore, indications of a caesarean section were analysed.

Results: The percentage of natural childbirths was similar in both groups. Furthermore, in both groups, over 80% of patients gave birth within less than 12 hours following dinoprostone administration. Neonatal outcomes (body weight, Apgar score) did not differ statistically. Analysing indications for a caesarean section, failure in the progress of labour was an indication in 39.5% of cases in the control group, 29.4% of cases in gestational diabetes mellitus (GDM), and 50% of cases in diabetes mellitus (DM). The risk of foetal asphyxia was an indication in 55.8% of cases in the control group, 35.3% of cases in GDM and 50% of cases in DM. Ineffective labour induction — no induction of the contractile function was an indication for a C-section in 4.7% of cases in the control group and 35.3% of cases in GDM; no cases were noted in DM (p = 0.024).

Conclusions: The study demonstrated that patients undergoing labour induction due to GDM using a dinoprostone vaginal insert did not differ in terms of labour duration, oxytocin administration compared to patients undergoing labour induction for other causes. Furthermore, the same rate of caesarean sections was found in the study group; however, these groups differ in terms of indications, including risk of foetal asphyxia (35.3% vs 55.8%), failure in the progress of labour (29.4% vs 39.5%), and no active labour (1.8% vs 1.5%). The neonatal Apgar score at 1.5 and 10 minutes after birth was similar in both groups.

Get Citation

Keywords

dinoprostone, induction of labor, gestational diabetes mellitus, GDM, cesarean delivery

About this article
Title

Influence of gestational diabetes mellitus on outcomes of preinduced labour with dinoprostone vaginal insert

Journal

Ginekologia Polska

Issue

Vol 94, No 7 (2023)

Article type

Research paper

Pages

539-543

Published online

2023-03-27

Page views

1210

Article views/downloads

312

DOI

10.5603/GP.a2023.0030

Pubmed

36976868

Bibliographic record

Ginekol Pol 2023;94(7):539-543.

Keywords

dinoprostone
induction of labor
gestational diabetes mellitus
GDM
cesarean delivery

Authors

Magdalena Kolak
Katarzyna Skibinska
Magda Rybak-Krzyszkowska
Agnieszka Micek
Tomasz Gora
Hubert Huras
Andrzej P. Jaworowski

References (23)
  1. Nicolosi BF, Souza RT, Mayrink J, et al. Preterm SAMBA Study Group. Incidence and risk factors for hyperglycemia in pregnancy among nulliparous women: A Brazilian multicenter cohort study. PLoS One. 2020; 15(5): e0232664.
  2. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S, et al. 2021 Guidelines on the management of patients with diabetes. A position of diabetes Poland. Clin Diabetol. 2021; 10(1): 1–113.
  3. Bomba-Opoń D, Drews K, Huras H, et al. Polish Gynecological Society Recommendations for Labor Induction. Ginekol Pol. 2017; 88(4): 224–234.
  4. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995; 854: 1–452.
  5. ACOG Practice Bulletin No. 107: Induction of Labor. Obstet Gynecol. 2009; 114(2): 386–397.
  6. Rosenstein MG, Cheng YW, Snowden JM, et al. The risk of stillbirth and infant death stratified by gestational age in women with gestational diabetes. Am J Obstet Gynecol. 2012; 206(4): 309.e1–309.e7.
  7. Metzger BE, Lowe LP, Dyer AR, et al. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008; 358(19): 1991–2002.
  8. Yildiz Atar H, Baatz JE, Ryan RM. Molecular mechanisms of maternal diabetes effects on fetal and neonatal surfactant. Children (Basel). 2021; 8(4).
  9. Capobianco G, Gulotta A, Tupponi G, et al. Materno-Fetal and neonatal complications of diabetes in pregnancy: a retrospective study. J Clin Med. 2020; 9(9): 2707.
  10. Quach D, Ten Eikelder M, Jozwiak M, et al. Maternal and fetal characteristics for predicting risk of Cesarean section following induction of labor: pooled analysis of PROBAAT trials. Ultrasound Obstet Gynecol. 2022; 59(1): 83–92.
  11. Spong CY, Mercer BM, D'Alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol. 2011; 118(2 Pt 1): 323–333.
  12. ACOG committee opinion no. 560: Medically indicated late-preterm and early-term deliveries. Obstet Gynecol. 2013; 121(4): 908–910.
  13. Alberico S, Erenbourg A, Hod M, et al. GINEXMAL Group. Immediate delivery or expectant management in gestational diabetes at term: the GINEXMAL randomised controlled trial. BJOG. 2017; 124(4): 669–677.
  14. Lurie S, Insler V, Hagay ZJ. Induction of labor at 38 to 39 weeks of gestation reduces the incidence of shoulder dystocia in gestational diabetic patients class A2. Am J Perinatol. 1996; 13(5): 293–296.
  15. Hawkins JS, Stephenson M, Powers B, et al. Diabetes mellitus: an independent predictor of duration of prostaglandin labor induction. J Perinatol. 2017; 37(5): 488–491.
  16. Bomba-Opoń D, Drews K, Huras H, et al. Polish Gynecological Society Recommendations for Labor Induction. Ginekol Pol. 2017; 88(4): 224–234.
  17. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol. 2018; 132(6): e228–e248.
  18. Practice Bulletin No. 137. Obstet Gynecol. 2013; 122(2): 406–416.
  19. Sutton AL, Mele L, Landon MB, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Delivery timing and cesarean delivery risk in women with mild gestational diabetes mellitus. Am J Obstet Gynecol. 2014; 211(3): 244.e1–244.e7.
  20. Mbele AM, Makin JD, Pattinson RC. Can the outcome of induction of labour with oral misoprostol be predicted. S Afr Med J. 2007; 97(4): 289–292.
  21. Yamaguchi M, Takakura S, Enomoto N, et al. Comparison of perinatal outcomes between controlled-release dinoprostone vaginal delivery system (PROPESS) and metreurynter for cervical ripening in labor induction: A retrospective single-center study in Japan. J Obstet Gynaecol Res. 2021; 47(12): 4256–4262.
  22. Coste Mazeau P, Hessas M, Martin R, et al. Is there an interest in repeating the vaginal administration of dinoprostone (Propess®), to promote induction of labor of pregnant women at term? (RE-DINO): study protocol for a randomized controlled trial. Trials. 2020; 21(1): 51.
  23. Timofeev J, Huang CC, Singh J, et al. Spontaneous labor curves in women with pregnancies complicated by diabetes. J Matern Fetal Neonatal Med. 2012; 25(1): 20–26.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl